Sykehuset I Vestfold HF
- Address
- lock Available on a paid plan
Gastroenterology and Immune-Mediated Disease
At Sykehuset I Vestfold HF, clinical research in digestive system diseases and immune system diseases focuses on ulcerative colitis and related inflammatory bowel conditions. These studies are designed to test new treatment options and better control long-term symptoms in people living with chronic intestinal inflammation.
- Improving remission and maintenance care in ulcerative colitis
- Evaluating therapies that target persistent inflammation in the gut
- Assessing symptom relief and quality of life for patients with chronic digestive disease
The site’s work in this area reflects a strong interest in advancing more effective and patient-friendly approaches for inflammatory bowel disease.
Oncology and Precision Cancer Medicine
Research in neoplasms at this hospital covers several cancers, including urothelial carcinoma, prostate cancer, lung cancer, and follicular lymphoma. The trials are mainly aimed at testing new anti-cancer treatments, improving outcomes after standard therapy, and exploring precision medicine approaches for advanced disease.
- Studying treatment options for metastatic urothelial cancer and recurrent bladder cancer
- Evaluating new strategies for multiple myeloma, lymphoma, and other blood cancers
- Exploring targeted therapies for patients with advanced malignancy
This research area includes efforts to match treatment more closely to tumor biology, with the goal of improving response and delaying disease progression.
Blood Cancers and Hematology
Clinical trials in hemic and lymphatic diseases are a major focus at the site, especially for multiple myeloma, myelodysplastic syndromes, chronic lymphocytic leukemia, and small lymphocytic lymphoma. The studies are intended to compare newer treatment combinations, improve disease control, and support deeper and longer-lasting remissions.
- Testing new therapies for relapsed or newly diagnosed multiple myeloma
- Assessing treatment options for CLL and SLL
- Evaluating care for anemia and lower-risk MDS
These trials highlight a broad hematology program aimed at improving survival, reducing transfusion needs, and strengthening long-term disease control.
Neurology and Stroke Care
Research in nervous system diseases includes studies in amyotrophic lateral sclerosis and acute ischemic stroke. The main purpose is to evaluate whether new treatments can slow neurological decline or improve recovery when time is critical after a stroke.
- Testing treatments for ALS that may slow progression
- Studying ways to improve early recovery after acute ischemic stroke
- Comparing approaches for stroke patients with complex treatment needs
This area shows the site’s involvement in both long-term neurodegenerative disease research and urgent hospital-based stroke care.
Respiratory and Viral Disease Research
The site is also active in respiratory tract diseases and virus diseases, with studies involving chronic obstructive pulmonary disease and COVID-19. These trials aim to reduce flare-ups, improve symptom control, and strengthen antiviral treatment strategies in vulnerable patients.
- Evaluating new options for COPD with frequent exacerbations
- Studying treatment strategies for COVID-19 in immunocompromised patients
- Assessing whether updated therapies can improve respiratory outcomes
Work in this area combines chronic lung disease management with infectious disease research, reflecting a practical focus on real-world patient needs.
Psychiatry, Addiction, and Mental Health
Clinical research in mental disorders and psychological phenomena includes studies on major depressive disorder and substance dependence involving amphetamines, benzodiazepines, and opioids. The trials are designed to improve symptom control, support recovery, and test better ways to manage dependence and treatment-resistant depression.
- Evaluating new approaches for treatment-resistant depression
- Studying care strategies for substance dependence and withdrawal management
- Assessing whether structured treatment can reduce illicit drug use
This field combines mental health and addiction research, with a strong focus on practical treatments that may improve daily functioning and long-term outcomes.
Cardiovascular, Eye, and Urgent Care Studies
Across cardiovascular diseases, eye diseases, and other urgent conditions, the site is involved in trials for central retinal artery occlusion and stroke-related care. These studies are aimed at improving emergency treatment and exploring whether faster intervention can preserve function and reduce disability.
- Testing emergency treatment for central retinal artery occlusion
- Evaluating treatment approaches for stroke in patients with specific medication histories
- Studying time-sensitive care to improve recovery after vascular events
These projects show a focus on rapid-response medicine, where early treatment may make a major difference in patient outcomes.
Endocrine, Kidney, and Reconstructive Symptom Care
Additional research at the medical department includes hormonal diseases, kidney-related conditions, and symptom-focused care after surgery. Trials involve primary adrenal insufficiency, IgA nephropathy, and low anterior resection syndrome, with the goal of improving day-to-day health, controlling disease activity, and easing ongoing symptoms.
- Studying improved hormone replacement for adrenal insufficiency
- Evaluating treatment for IgA nephropathy and protein loss in the urine
- Assessing symptom relief in low anterior resection syndrome
This part of the portfolio highlights care that goes beyond disease treatment alone, including quality-of-life and symptom management research.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Top 4 of 17 therapeutic areas and 15 of 93 IMPs, ranked by number of trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Top 40 of 89 compounds, ranked by number of trials.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 23 by active trials.
- 1Oslo University Hospital HF4active
lock +22 more on a paid plan
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
- 1Oslo University Hospital HF6trials
lock +5 more on a paid plan
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 112 other sites in Norway
Therapeutic Area Benchmark — Norway
Select a therapeutic area to compare against other sites in Norway.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: Norway
Market Share
Country: Norway
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in Sykehuset I Vestfold HF
lock Showing 1 of 30 trials — the rest is available on a paid plan.
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| A Phase III, Multicentre, Randomized, Double-blind, Chronic-dosing, Parallel-group, Placebo-controlled Study to Evaluate the Efficacy and Safety of Two Dose Regimens of Tozorakimab in Participants with Symptomatic Chronic Obstructive Pulmonary Disease (COPD) with a History of COPD Exacerbations (Oberon) | AstraZeneca AB | Phase III | Not Recruiting | Jan 2022 | Mar 2026 |
IMP list
lock Showing 1 of 93 compounds — the rest is available on a paid plan.
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| Dexamethasone | 4 | Unknown | 2021-04-01 | 2025-09-30 |
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.
